Arrowhead Pharmaceuticals (ARWR)
(Delayed Data from NSDQ)
$20.80 USD
-0.34 (-1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $20.79 -0.01 (-0.05%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Arrowhead Pharmaceuticals, Inc falls in the month of September.
All items in Millions except Per Share data.
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 404 | 376 | 368 | 315 | 259 |
Receivables | 0 | 1 | 10 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 16 | 27 | 7 | 6 | 6 |
Total Current Assets | 420 | 405 | 385 | 322 | 265 |
Net Property & Equipment | 290 | 110 | 49 | 31 | 23 |
Investments & Advances | 0 | 106 | 246 | 137 | 44 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 10 | 12 | 14 | 15 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 766 | 692 | 710 | 523 | 350 |
Liabilities & Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 36 | 3 | 9 | 7 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 58 | 59 | 24 | 13 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 74 | 111 | 19 | 78 |
Total Current Liabilities | 105 | 139 | 147 | 41 | 97 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 56 | 132 | 0 | 9 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 268 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 478 | 274 | 301 | 61 | 106 |
Shareholders Equity | 9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | 9/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,300 | 1,219 | 1,053 | 965 | 664 |
Retained Earnings | -1,026 | -821 | -645 | -504 | -419 |
Other Equity | 13 | 20 | 0 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 287 | 418 | 409 | 462 | 244 |
Total Liabilities & Shareholder's Equity | 766 | 692 | 710 | 523 | 350 |
Total Common Equity | 287 | 418 | 409 | 462 | 244 |
Shares Outstanding | 107.10 | 105.80 | 104.20 | 102.20 | 94.80 |
Book Value Per Share | 2.68 | 3.95 | 3.92 | 4.52 | 2.57 |
Fiscal Year End for Arrowhead Pharmaceuticals, Inc falls in the month of September.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 437 | 523 | 220 | 404 | 452 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 19 | 18 | 16 | 17 |
Total Current Assets | 450 | 542 | 238 | 420 | 470 |
Net Property & Equipment | 376 | 359 | 333 | 290 | 231 |
Investments & Advances | 0 | 0 | 0 | 0 | 43 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 9 | 9 | 10 | 10 | 11 |
Deposits & Other Assets | 4 | 0 | 0 | 0 | 0 |
Total Assets | 884 | 955 | 626 | 766 | 796 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 27 | 9 | 4 | 36 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 64 | 51 | 55 | 58 | 43 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 0 | 1 | 17 |
Total Current Liabilities | 97 | 65 | 64 | 105 | 70 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 336 | 274 | 268 | 264 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 545 | 460 | 453 | 478 | 414 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,786 | 1,769 | 1,320 | 1,300 | 1,281 |
Retained Earnings | -1,455 | -1,284 | -1,159 | -1,026 | -916 |
Other Equity | 7 | 11 | 12 | 13 | 17 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 339 | 495 | 174 | 287 | 382 |
Total Liabilities & Shareholder's Equity | 884 | 955 | 626 | 766 | 796 |
Total Common Equity | 339 | 495 | 174 | 287 | 382 |
Shares Outstanding | 124.20 | 123.90 | 123.10 | 107.10 | 106.90 |
Book Value Per Share | 2.73 | 4.00 | 1.41 | 2.68 | 3.57 |